Condition (MeSH)
Basal Cell Nevus Syndrome
ClinicalTrials.gov lists 35 trials for Basal Cell Nevus Syndrome or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
35 of the 35 trials are tagged with Basal Cell Nevus Syndrome itself; the rest are tagged with a narrower condition beneath it.
When did Basal Cell Nevus Syndrome trials start? (15)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 3
- Not applicable
- Observational
Top of scale: 3
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2024 | 3 |
| 2023 | 1 |
| 2021 | 2 |
| 2020 | 2 |
| 2019 | 3 |
| 2018 | 1 |
| 2017 | 2 |
| 2016 | 3 |
| 2015 | 2 |
| 2014 | 3 |
Showing 10 of 15 earlier years.
No forecast is made for this condition: it averages 1.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 35 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Basal Cell Nevus Syndrome trials in? (7)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 3 |
| Phase 1/2 | 2 |
| Phase 2 | 15 |
| Phase 2/3 | 1 |
| Phase 3 | 4 |
| Not applicable | 3 |
| Observational | 7 |
How many Basal Cell Nevus Syndrome trials are recruiting? (7)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 3 |
| Enrolling by invitation | 1 |
| Completed | 22 |
| Suspended | 1 |
| Terminated | 5 |
Showing 5 of 7 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Basal Cell Nevus Syndrome trials? (7)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Novartis Pharmaceuticals | 4 |
| Sol-Gel Technologies, Ltd. | 4 |
| Ascend Biopharmaceuticals Ltd | 3 |
| PellePharm, Inc. | 2 |
| Children's Oncology Group | 1 |
Showing 5 of 7 sponsors.
Which drugs are being tested for Basal Cell Nevus Syndrome? (4)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Vismodegib | 4 |
| Gusacitinib | 3 |
| Tazarotene | 2 |
| Patidegib | 2 |
Interventions as named in the registry (11)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| LDE225B | 4 |
| Patidegib Topical Gel, 2% | 3 |
| Patidegib Topical Gel, Vehicle | 2 |
| Vehicle Gel | 2 |
| Patidegib Topical Gel | 1 |
Showing 5 of 11 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Basal Cell Nevus Syndrome trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Weight loss | 6 | 1 |
| Pneumonia | 4 | 3 |
| Abdominal pain | 3 | 2 |
| Basal cell carcinoma | 2 | 2 |
| Chest pain | 2 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Basal Cell Nevus Syndrome? (12)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial. | European journal of cancer (Oxford, England : 1990) | 2017 | Yes |
| Inhibition of the hedgehog pathway in patients with basal-cell nevus syndrome: final results from the multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. | The Lancet. Oncology | 2016 | Yes |
| Tazarotene: randomized, double-blind, vehicle-controlled, and open-label concurrent trials for basal cell carcinoma prevention and therapy in patients with basal cell nevus syndrome. | Cancer prevention research (Philadelphia, Pa.) | 2014 | Yes |
| The use of vismodegib to shrink keratocystic odontogenic tumors in patients with basal cell nevus syndrome. | JAMA dermatology | 2014 | Yes |
| Surgical excision after neoadjuvant therapy with vismodegib for a locally advanced basal cell carcinoma and resistant basal carcinomas in Gorlin syndrome. | JAMA dermatology | 2013 | Yes |
Showing 5 of 12 publications.
Prevalence (21)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Gorlin syndrome | Prevalence at birth | 1-9 / 100 000 | United Kingdom | GB | Unspecified |
| Gorlin syndrome | Point prevalence | 1-9 / 100 000 | United Kingdom | GB | Exact |
| Gorlin syndrome | Prevalence at birth | 1-9 / 100 000 | United Kingdom | GB | Exact |
| Gorlin syndrome | Point prevalence | 1-9 / 100 000 | United Kingdom | GB | Unspecified |
| Gorlin syndrome | Point prevalence | 1-9 / 100 000 | United Kingdom | GB | Exact |
Showing 5 of 21 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Gorlin syndrome | 377 | Exact | Orphanet Rare Disease Ontology (ORDO) |
| Gorlin syndrome | 377 | Exact | Orphadata Science knowledge files, Product 1 |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: sub-conditions in mesh.